Conference Call with IOL Chemicals and Pharmaceuticals Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.
Highlights: IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of pharmaceutical (APis) and specialty chemicals today posted its financial results for the quarter and half year ending 30th September 2021. The Company on QoQ basis recorded 5% growth in total income, however the EBITDA has been declined by about 53% on QoQ basis. Dr Sanjay Chaturvedi, Chief Executive Officer said ''During the quarter ended September 2021, the Company's performance has been muted presently due to contraction in flagship API demand and volatility in raw material prices of Chemical products. He further stated that revenue from new products in pharma API has been getting positive response." Result PDF
Highlights IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of pharmaceutical (APIs) and specialty chemicals today posted its financial results for the quarter ending 30th June 2021. The Company on QoQ & YoY basis recorded 12% growth in total income, however the EBITDA has been almost flat on QoQ and declined by about 27% on YoY basis on account of stressed demand primarily due to 2nd wave of Covid-19 globally. Dr Sanjay Chaturvedi, Chief Executive Officer said “During the quarter ended June 2021, the Company’s performance has been satisfactory in spite of difficult operating conditions faced by the Company during surged situation of Covid-19 pandemic. The Chemicals segment performed very well during the quarter both in terms of top line and bottom line. He also added, the Company completed the installation of new manufacturing facilities ‘Unit -10’ to manufacture multiple Pharma (API’s) products including Fenofibrate, Lamotrigine and Ursodeoxycholic Acid (UDCA) to cater the growing demand. Talking about future projects, he added that the installation of new manufacturing facilities 'Unit -9' for manufacturing Gabapentin & other pharma (APIs) products is slightly delayed of its schedule due to 2nd wave of Covid-19 and expected to complete in 3rd quarter of FY22 without any cost overrun." Result PDF